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Abstract
Dendritic cells (DCs) comprise heterogeneous subsets of
professional antigen-presenting cells, linking innate and
adaptive immunity. Analysis of DC subsets has been hampered
by a lack of specific DC markers and reliable quantitation
assays. We characterised the immunophenotype and functional
characteristics of psoriatic arthritis (PsA)-derived and
rheumatoid arthritis (RA)-derived myeloid DCs (mDCs) and
plasmacytoid DCs (pDCs) to evaluate their potential role in
arthritis. Circulating peripheral blood (PB) pDC numbers were
significantly reduced in PsA patients (P  = 0.0098) and RA
patients (P = 0.0194), and mDCs were significantly reduced in
RA patients (P = 0.0086) compared with healthy controls. The
number of circulating mDCs in RA PB was significantly inversely
correlated to C-reactive protein (P = 0.021). The phenotype of
both DC subsets in PsA PB and RA PB was immature as
compared with healthy controls. Moreover, CD62L expression
was significantly decreased on both mDCs (PsA, P = 0.0122;
RA, P = 0.0371) and pDCs (PsA, P = 0.0373; RA, P = 0.0367)
in PB. Both mDCs and pDCs were present in PsA synovial fluid
(SF) and RA SF, with the mDC:pDC ratio significantly exceeding
that in matched PB (PsA SF, P = 0.0453; RA SF, P = 0.0082).
pDCs isolated from RA SF and PsA SF displayed an immature
phenotype comparable with PB pDCs. RA and PsA SF mDCs,
however, displayed a more mature phenotype (increased
expression of CD80, CD83 and CD86) compared with PB
mDCs. Functional analysis revealed that both SF DC subsets
matured following toll-like receptor stimulation. pDCs from PB
and SF produced interferon alpha and tumour necrosis factor
alpha on TLR9 stimulation, but only SF pDCs produced IL-10.
Similarly, mDCs from PB and SF produced similar tumour
necrosis factor alpha levels to TLR2 agonism, whereas SF
mDCs produced more IL-10 than PB controls. Circulating DC
subset numbers are reduced in RA PB and PsA PB with
reduced CD62L expression. Maturation is incomplete in the
inflamed synovial compartment. Immature DCs in SF may
contribute to the perpetuation of inflammation via sampling of
the inflamed synovial environment, and in situ presentation of
arthritogenic antigen.
Introduction
The inflammatory arthritides, including rheumatoid arthritis
(RA) and psoriatic arthritis (PsA), comprise autoimmune disor-
ders characterised by chronic joint inflammation, immune cell
infiltration to the synovium, fibroblast-like synoviocyte expan-
sion and destruction of cartilage and bone. Extensive in vivo
and in vitro studies have identified multiple proinflammatory
cytokines and enzymes implicated in the pathogenesis of both
of these disorders. Targeting cytokines has proven therapeuti-
cally useful, exemplified particularly in tumour necrosis factor
(TNF) blockade and more recently in targeting IL-6 and IL-15
[1-4]. Cytokine blockade, however, exhibits variable
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responses across patient populations – and, importantly, dis-
ease activity recurs upon cessation of therapy. A major chal-
lenge in therapeutics now is to develop strategies that re-
establish immune tolerance such that amelioration of inflam-
mation is accompanied by long-term disease suppression.
Early evidence that such responses may be feasible is derived
from clinical studies utilising CTLA-4Ig [5] and anti-CD20
[6,7] in RA, and using co-stimulatory blockade in psoriasis [8-
10].
Many data indicate the presence and significance of autoim-
mune processes in articular inflammation. Recent results in RA
patients implicate citrullinated peptides in disease progres-
sion and response to TNF blockade [11]. Additional auto-spe-
cific antigens include type II collagen [12] and cartilage-
derived gp39 [13,14]. Although few autoimmune targets have
been identified in PsA, perhaps reflecting the absence thus far
of defined autoantibodies, analysis of PsA synovial and skin T
cell subsets clearly indicates oligoclonal responses that may
be self-targeted [15,16]. Critically, in both diseases, upstream
immunological processes have been poorly characterised ex
vivo, particularly with respect to the site and nature of antigen
presentation. Antigen-presenting macrophages and B cells
play a potential role in synovial inflammation, especially in
mediating cartilage degradation [17,18]. However, the role
played by various subsets of dendritic cells (DCs) is less clear
[19]. Although enrichment of DCs in RA synovial tissue and
fluid and in seronegative synovial fluid has been reported [20-
26], the considerable phenotypic, morphologic and functional
variations between DC subsets related to lineage, stage of
maturation and tissue localisation remains less well under-
stood. This partly reflects the difficulty in adequately identifying
DC subsets in peripheral blood (PB) and tissues where most
methodologies rely on complex combinations of surface
markers.
Novel markers that resolve these issues, useful in human DC
studies, have been recently defined [27]. Five distinct subsets
of lineage-negative HLA-DR+ DCs have been classified in
humans. Four subsets – CD1b/c+, CD16+, blood dendritic
cell antigen (BDCA)-3+ and CD34+ – are myeloid-lineage
derived, while the fifth subset – CD123 (IL-3Rα+)/CD303
(BDCA-2)+ – has a lymphoid phenotype and is described as a
plasmacytoid DC (pDC) [27,28]. Comprising 0.5–1.0% of all
Figure 1
Enumeration of dendritic cell subsets in various arthritides and healthy volunteers Enumeration of dendritic cell subsets in various arthritides and healthy volunteers. Plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells 
(mDCs) are significantly decreased in rheumatoid arthritis (RA) peripheral blood (PB), and pDCs are significantly decreased in psoriatic arthritis 
(PsA) PB. The total number of (a) mDCs and (c) pDCs per millilitre of PB and the percentage of (b) mDCs and (d) pDCs of white blood cells (WBC) 
in healthy subjects (n = 12), RA subjects (n = 12), PsA subjects (n = 13) and osteoarthritis (OA) subjects (n = 11). Squares indicate individual sam-
ples. -, median. *P < 0.05, **P < 0.01.Available online http://arthritis-research.com/content/8/1/R15
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circulating mononuclear cells, myeloid DCs (mDCs) are char-
acterised as CD1c+/CD11c+/CD45RO+/HLA-DR+/CD123
(IL-3Rα)lo. Capable of IL-12-p70, IL-6, TNF-α and IL-10 pro-
duction in response to bacterial or CD40L stimulation as well
as antigen capture and presentation [29], mDCs require gran-
ulocyte–macrophage colony-stimulating factor (GM-CSF) for
survival in vitro and can differentiate into interstitial DCs and
Langerhans cells in the presence of GM-CSF, IL-4 and tumour
growth factor beta [30]. Conversely pDCs, characterised as
CD303 (BDCA-2)+/CD304 (BDCA-4)+/CD123 (IL-3Rα)high/
CD11c-/HLA-DR+/CD45RA+, comprise less than 0.3% of all
circulating mononuclear cells and secrete large amounts of
the type I interferons (IFNs) in response to herpes or influenza
virus stimulation [31,32].
It has been suggested that DCs play a role in the initiation and
perpetuation of inflammatory arthritis by presentation of arthri-
togenic antigens to autoreactive T cells [19,33-35]. This pres-
entation may drive aberrant memory T cell responses,
promoting B cell activation and immunoglobulin class switch-
ing. DC infiltration into the synovium occurs early in the dis-
ease pathology [19,36,37]. DCs could represent important
cellular targets in inflammatory synovitis, by virtue of their
potent antigen presentation potential and their capacity to pro-
mote local inflammation via toll-like receptor (TLR) expression
[38,39] and cytokine release [31,40-43]. Recent advances in
identifying DC subsets have improved the resolution of subset
heterogeneity. We therefore utilised robust assays to quantify
and characterise the distribution and phenotype of mDCs and
pDCs in blood from PsA patients and RA patients in compari-
son with osteoarthritis (OA) patients and healthy donors and
synovial fluid (SF) from PsA patients and RA patients. We also
investigated the functional capabilities of mDCs and pDCs
isolated from SF to mature and release cytokines upon TLR
stimulation.
Materials and methods
Patients and controls
Inflammatory arthritis patients fulfilled the American College of
Rheumatology (formerly the American Rheumatism Associa-
tion) criteria for RA [44], or met diagnostic criteria for PsA as
previously described [45,46]. All patients and healthy donors
gave informed consent and the study protocol was approved
by the Ethical Committee, Glasgow Royal Infirmary. PB was
obtained from patients with RA (n = 12), from patients with
PsA (n = 13) and from patients with OA (n = 11), and was
compared with healthy controls (n = 12). SF was obtained
from a subset of these donors (RA, n = 6; PsA, n = 6). All cell
analysis was undertaken on freshly isolated cells.
For cytokine investigation, cell-free SF and supernatants from
cell culture were stored in the Centre for Rheumatic Disease
Biobank at -70°C until analysis. Patients were attending the
Centre for Rheumatic Diseases, Glasgow Royal Infirmary. At
the time of the study, RA patients were receiving methotrexate
(n = 7), sulphasalazine (n = 8) or hydroxychloroquine (n = 4),
Table 1
Patient data
Characteristic Peripheral blood study group Synovial fluid study group
Rheumatoid arthritis Age [mean ± SD (range)] 58 ± 12 (24–80) 59 ± 15 (33–70)
Female:male 10:2 5:1
White blood cells [mean ± SEM] 6.4 × 106 ± 1.2 × 104/ml
C-reactive protein 26 ± 6 (6–100) 22 ± 7 (6–41)
Psoriatic arthritis Age [mean ± SD (range)] 42 ± 14 (24–81) 41 ± 15 (25–50)
Female:male 10:3 5:1
White blood cells [mean ± SEM] 8.0 × 106* ± 4.5 × 105/ml
C-reactive protein 14 ± 4 (6–73) 30 ± 15 (6–73)
Osteoarthritis Age [mean ± SD (range)] 63 ± 12 (52–82)
Female:male 4:6
White blood cells [mean ± SEM] 6.0 × 106 ± 8.9 × 105/ml
C-reactive protein 10 ± 3 (6–14)
Healthy Age [mean ± SD (range)] 44 ± 11
Female:male 6:6
White blood cells [mean ± SEM] 6.4 × 106 ± 4.7 × 105/ml
SD, standard deviation; SEM, standard error of the mean.
*P < 0.05 compared with healthy control peripheral blood.Arthritis Research & Therapy    Vol 8 No 1    Jongbloed et al.
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or a combination of these agents (n = 5). PsA patients were
receiving either methotrexate (n = 11) or sulphasalazine (n =
4), or a combination of these agents (n = 2). OA patients did
not receive any standard immune modulatory therapy. Patients
on oral steroids were excluded from the study.
Enumeration of DC subsets in PB and SF
Circulating DC populations were identified by flow cytometry
using the FACScalibur system (Becton Dickinson, San Jose,
CA, USA) and using a circulating DC enumeration kit (Miltenyi
Biotech, Bergisch Gladbach, Germany) according to the man-
ufacturer's instructions (Blood Dendritic Cell Enumeration Kit;
Miltenyi Biotech). Briefly, a white blood cell (WBC) count was
calculated from PB and SF samples using a Coulter Counter
(Beckman Coulter, Fullarton, CA, USA). Aliquots of whole
blood were labelled with a cocktail of antibodies including anti-
CD14-phycoerythrin (PE).Cy5 and anti-CD19-PE.Cy5 plus or
minus anti-CD1c-PE (mDC marker) and CD303 (BDCA-2)-
fluorescein isothiocyanate (FITC) (pDC marker) or mouse
IgG2a-PE and mouse IgG1-FITC antibodies. A proprietary
dead cell discriminator was also included. After incubation,
red cell lysis and washing, cells were fixed and examined using
a FACScalibur and were analysed using Cellquest software
(both Becton Dickinson). Results are expressed as the per-
centage of mDCs or pDCs in WBCs or as absolute numbers
per millilitre of PB/SF (calculated as [% positive - % negative
cells] × WBCs per ml [×106/100]).
Isolation of pDCs and mDCs from PB and SF
Both PB and SF samples were diluted in phosphate-buffered
saline and mononuclear cells isolated by density gradient cen-
trifugation over histopaque®-1077 (Sigma-Aldrich, Poole,
Dorset, UK) and pDCs and mDCs sequentially purified by
magnetic cell sorting (Miltenyi Biotec) using a high gradient
Mini-MACS® device. pDCs were purified by positive selection
using anti-CD304 (BDCA-4)-conjugated magnetic
microbeads (Miltenyi Biotec). B cells were depleted using anti-
CD19-conjugated magnetic microbeads (Miltenyi Biotec)
prior to mDC purification via incubation with biotin-conjugated
anti-CD1c and anti-biotin-conjugated magnetic microbeads
(both Miltenyi Biotec). FACScan analysis determined that the
isolated cell populations from PB and SF were >95% and
>93% pure, respectively (<10% neutrophil contamination).
Isolated DCs were phenotyped using the following mono-
clonal antibodies: CD1c-FITC (mDCs only), CD303 (BDCA-
2)-FITC (pDCs only) and CD123-PE (pDCs only) (all Miltenyi
Biotec), CCR5-PE (R&D Systems, Minneapolis, MN, USA)
(pDCs only), and CD11c-PE (mDCs only), CD14-PE (mDCs
only), CD40-APC, CD62L-FITC, CD80-FITC, CD83-APC,
CD86-APC and CCR7-PE (all BD Biosciences Pharmingen,
San Diego, CA, USA).
mDC and pDC stimulation
All cells were cultured in RPMI-1640 supplemented with 5%
human AB serum, L-glutamine (2 mM), penicillin (100 IU/ml),
streptomycin (100 µg/ml) and amphotericin B (1.25 µg/ml) (all
Sigma-Aldrich). Isolated mDCs were incubated in triplicate at
(1–5) × 105/ml containing 50 ng/ml GM-CSF (StemCell
Technologies, Vancouver, BC, Canada) alone, or supple-
mented with Staphylococcus aureus peptidoglycan (PGN) at
10  µg/ml or CpG oligodeoxynucleotide (ODN) 2216
(ggGGTCAAGCTTGAgggggG) at 3.2 µg/ml (both InVivogen,
San Diego, CA, USA). Isolated pDCs were incubated in tripli-
cate at (1–5) × 105/ml containing 20 ng/ml IL-3 (StemCell
Technologies) alone or supplemented with CpG ODN 2216
at 3.2 µg/ml or ODN 2216c (control for CpG ODN 2216)
(ggGGGAGCATGCTCgggggG) at 3.2 µg/ml (both InVivo-
gen). cultures were centrifuged after 24 hours, supernatants
collected and stored at -20°C until analysis, and phenotypical
analysis by FACScalibur was performed as stated earlier.
Figure 2
Relationship of DC numbers to acute phase response Relationship of DC numbers to acute phase response. Circulating mye-
loid dendritic cell (mDC) numbers are significantly inversely correlated 
to C-reactive protein (CRP) levels in rheumatoid arthritis (RA) periph-
eral blood (PB). The CRP levels of RA patients (n = 12) compared with 
total numbers of (a) mDCs and (b) plasmacytoid dendritic cells (pDCs) 
per millilitre of PB. CRP levels are calculated on a logarithmic scale, 
and squares indicate individual samples. *P < 0.05.Available online http://arthritis-research.com/content/8/1/R15
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Cytokine analysis
Levels of IFN-α in pDC culture supernatants and SF samples
were measured using a human IFN-α ELISA (Bender MedSys-
tems™, San Bruno, CA, USA) according to the manufacturer's
instructions. Levels of IL-10 and TNF-α in mDC and pDC cul-
ture supernatants were assessed using a Luminex kit (Bio-
Source, Nivelles, Belgium) according to the manufacturer's
instructions. Results of all cytokine analysis were normalised
to 5 × 104 cells per sample.
Statistical analysis
Data are expressed as the median and interquartile range. Sta-
tistical significance was determined using the nonparametric
Mann-Whitney U test between disease groups and healthy
controls. C-reactive protein (CRP) correlation to PB DC num-
bers was analysed by Spearman Rank correlation. P < 0.05
was considered significant.
Results
Numbers and proportion of circulating pDCs decreased 
in PsA BP and RA PB, and mDCs decreased in RA PB
The synovial compartment has been the focus of many previ-
ous studies of RA and PsA [16,47]. We chose to examine
both the systemic and local levels of circulating DC subsets in
inflammatory arthritis, as changes in DC subpopulations have
been identified in other autoimmune diseases, particularly sys-
temic lupus erythematosus [41,48-50]. PB was obtained from
RA patients (n = 12) and PsA patients (n = 13) and was com-
pared with PB from OA patients (n = 11) and healthy controls
(n = 12).
In RA PB, mDCs were significantly decreased compared with
healthy controls, expressed as total numbers per millilitre of PB
(Figure 1a) (P = 0.0086) and as a percentage of WBCs (Fig-
ure 1b) (P = 0.0262). In PsA PB, mDCs were not significantly
decreased compared with healthy controls when expressed
as total numbers per millilitre of PB (P = 0.1147) but were sig-
nificantly decreased when adjusted to the percentage of
WBCs (P = 0.018), most probably reflecting an elevation in
another cell population as indicated by a significantly
increased WBC count in PsA PB compared with healthy con-
trols (Table 1, P = 0.0470).
In contrast, circulating pDCs were significantly decreased in
both RA PB and PsA PB compared with healthy controls
expressed either as total numbers per millilitre of PB (Figure
1c) (RA, P = 0.0194; PsA, P = 0.0098) or indeed as a per-
centage of WBCs (Figure 1d) (RA, P = 0.0180; PsA, P =
0.0051). In OA PB, although a trend towards a decrease in
pDC numbers per millitre of PB was observed, neither mDC
nor pDC numbers were significantly reduced compared with
Figure 3
Phenotypic characterisation of blood derived DC subsets Phenotypic characterisation of blood derived DC subsets. Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) peripheral blood (PB) plasmacytoid 
dendritic cells (pDCs) and myeloid dendritic cells (mDCs) have an immature phenotype and significantly decreased CD62L expression. (a) Migra-
tion and maturation markers on CD1c+/CD11c+ mDCs purified from RA PB (n = 5) and from PsA PB (n = 5) compared with healthy control PB (n 
= 5). (b) CD303 (BDCA-2)+/CD123+ pDCs purified from RA PB (n = 5) and from PsA PB (n = 5) compared with healthy control PB (n = 5). Values 
are calculated as the mean fluorescent intensity (MFI) fold of the increase above the isotype control. The median and interquartile range is shown. *P 
< 0.05.Arthritis Research & Therapy    Vol 8 No 1    Jongbloed et al.
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healthy controls whether data were expressed as a percent-
age of total WBCs or as total cell numbers per millilitre of PB.
Reduced RA PB mDC numbers are inversely correlated 
to CRP
The significant decrease of pDCs and mDCs in RA PB and of
pDCs in PsA PB, as well as the trend towards a decrease in
pDCs in OA PB, were intriguing and led us to investigate a
possible correlation to the magnitude of inflammatory disease
activity. Accordingly, we analysed pDC and mDC numbers
from PB of RA patients, PsA patients and OA patients com-
pared with serum CRP concentrations. The mDC numbers per
millilitre of PB, but not the pDC numbers per millilitre, were sig-
nificantly inversely correlated to CRP levels from RA patients
(P = 0.021, r = -0.45233 and P = 0.228, r = -0.4001, respec-
tively) (Figure 2a,b). Neither mDC nor pDC numbers per milli-
litre of PB were significantly inversely correlated to serum CRP
concentrations from PsA patients or OA patients. This could
reflect the relatively poorer utility of CRP as a surrogate for dis-
ease activity in the latter conditions.
CD62L is aberrantly expressed on RA and PsA circulating 
PB DCs
To further study the phenotype of PB mDCs and pDCs, these
cells were isolated in a subset of RA PB (n = 5) and PsA PB
(n = 5) and were compared with healthy controls (n = 5). The
purity of the isolated DCs was confirmed by double staining
with CD1c and CD11c for mDCs (Figure 3a) and with CD303
(BDCA-2) and CD123 for pDCs (Figure 3b); this purity was
routinely >99% mDCs and >95% pDCs. Fluorescence-acti-
vated cell sorting analysis indicated that both CD1c+/CD11c+
mDCs and CD303 (BDCA-2)+/CD123+ pDCs from PsA PB
and RA PB displayed an immature phenotype similar to mDCs
and pDCs isolated from healthy controls (Figure 3a,b, respec-
tively), with absent expression of the maturation marker CD83
and low to absent expression of CD40, CD80 and CD86 and
the chemokine receptor CCR7. However, expression of the
adhesion molecule CD62L (L-selectin) was significantly
reduced on inflammatory arthritis-derived mDCs (RA, P  =
0.0371; PsA, P = 0.0122) and pDCs (RA, P = 0.0367; PsA,
P = 0.0373) compared with healthy control PB mDCs and PB
pDCs, respectively.
RA SF and PsA SF contain mDCs and pDCs
The aforementioned data strongly suggest that DC subset dis-
tribution in inflammatory arthritis is abnormal and commensu-
rate with either enhanced migration to the synovial
compartment or reduced release from bone marrow. To inves-
tigate the former possibility, we chose to evaluate DC subsets
in SF. To this aim, we enumerated mDCs and pDCs in SF and
matched PB obtained from six patients with RA and from six
patients with PsA.
Magnetic sorting and flow cytometry revealed that, whereas
absolute mDC and pDC numbers varied greatly between indi-
vidual patients, both were consistently present in RA SF and
PsA SF (Table 2). The mDC:pDC ratio in PB was approxi-
mately 2:1 in both RA patients and PsA patients, and was sim-
ilar to that seen in OA patients and healthy controls (Figure
4a). In contrast, this ratio was significantly increased in both
RA SF (median, 9.4:1; P = 0.0082) and PsA SF (median,
6.05:1; P = 0.0453) (Figure 4b) compared with matched PB.
SF mDCs have a semi-mature phenotype but pDCs are 
immature
To investigate the phenotype of mDCs and pDCs in SF, cells
were isolated from a subset of RA SF (n = 3) and PsA SF (n
= 4), as stated earlier, and were analysed using a range of cell
surface markers. Isolated DC subsets were routinely >90%
pure, and the phenotype was determined by gating specifically
on CD1c+/CD11c+ cells (mDCs) and CD303 (BDCA-2)+/
CD123+ cells (pDCs). In both RA SF (Figure 5a) and PsA SF
(Figure 5b) the phenotype of mDCs was similar, with
increased expression of CD40, CD80, CD83 and CD86 in
comparison with their RA PB and PsA PB counterparts,
respectively, indicating a semi-mature phenotype. In contrast,
Figure 4
Ratios of DC subsets in tissue compartments Ratios of DC subsets in tissue compartments. Myeloid dendritic cell/
plasmacytoid dendritic cell (mDC:pDC) ratios in synovial fluid (SF) are 
significantly increased when compared with matched peripheral blood 
(PB). (a) The mDC:pDC ratio in PB from rheumatoid arthritis (RA) sub-
jects (n = 12), psoriatic arthritis (PsA) subjects (n = 13) and osteoar-
thritis (OA) subjects (n = 11) was not significantly altered compared 
with healthy control subjects (n = 12); median and interquartile range 
are shown. (b) The mDC:pDC ratio in SF from RA subjects (n = 6) and 
PsA subjects (n = 6) was significantly increased compared with 
matched PB samples. Squares indicate individual matched samples. 
The ratio was calculated from total number of cells per millilitre. *P < 
0.05, **P < 0.01.Available online http://arthritis-research.com/content/8/1/R15
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RA SF (Figure 5c) and PsA SF (Figure 5d) pDCs displayed an
immature phenotype, generally comparable with that of circu-
lating PB pDCs, with low to absent expression of CD40,
CD80 and CD83.
The only difference observed was an increase of CD86
expression on PsA SF pDCs compared with PsA PB pDCs,
although this was not observed on RA SF pDCs. Since
CD62L was significantly reduced, but not absent, on mDCs
and pDCs from RA PB and PsA PB, we also evaluated expres-
sion on SF-derived cell subsets. CD62L was decreased on
mDCs and pDCs from both RA SF and PsA SF DC subsets
compared with RA PB and PsA PB.
The presence of relatively large numbers of immature pDCs in
SF was intriguing, since immature pDCs characteristically pro-
duce high levels of IFN-α [51]. The level of IFN-α expression in
inflammatory synovial fluids is little characterised and declared
absent in previous publications [52]. We therefore analysed
RA SF (n = 18), PsA SF (n = 14) and OA SF (n = 7) for the
presence of IFN-α by ELISA (Figure 6). By this methodology,
IFN-α was detectable in many SFs, derived not only from RA
and PsA samples but also from a small number of OA SF.
However, there were no significant differences between
diseases.
SF mDCs and pDCs mature and release cytokines upon 
TLR stimulation
It is now recognised that DCs are activated via TLRs [39].
TLR-induced cytokine production was therefore evaluated in
disease DCs compared with healthy PB-derived DCs. We
purified mDCs and pDCs as already mentioned and evaluated
the addition of the TLR2 agonist S. aureus PGN (for mDCs)
or the TLR9 agonist CpG ODN 2216 (for pDCs) over 24
hours. For control purposes, mDCs were also incubated with
GM-CSF alone or the irrelevant TLR agonist CpG ODN 2216
(mDCs do not express TLR9), and pDCs were also incubated
with IL-3 alone or with control ODN 2216c. The phenotypic
Figure 5
Phenotypic characterisation of synovial DC subsets Phenotypic characterisation of synovial DC subsets. Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) synovial fluid (SF) plasmacytoid dendritic 
cells (pDCs) have an immature phenotype, but myeloid dendritic cells (mDCs) have a semi-mature phenotype. Migration and maturation markers on 
CD1c+/CD11c+ mDCs purified from (a) RA SF (n = 3) compared with RA peripheral blood (PB) (n = 5) and (b) PsA SF (n = 3) compared with PsA 
PB (n = 5), and CD303+/CD123+ pDCs purified from (c) RA SF (n = 3) compared with RA PB (n = 5) and (d) PsA SF (n = 3) compared with PsA 
PB (n = 5). Values are calculated as the mean fluorescent intensity (MFI) fold of the increase above the isotype control. The median and interquartile 
range are shown. *P < 0.05Arthritis Research & Therapy    Vol 8 No 1    Jongbloed et al.
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changes in DC subsets were measured by fluorescence-acti-
vated cell sorting analysis and the cytokine release was meas-
ured by multiplex assay or ELISA. Irrelevant TLR agonists did
not induce cytokine production in any culture conditions
tested, nor did they have any effect on in vitro maturation of
DC subsets (data not shown).
Distinct patterns of cytokine production emerged on compari-
son of PB-derived versus SF-derived mDCs and pDCs. In
PGN-stimulated cultures, mDCs from both PB and SF pro-
duced comparable levels of TNF-α (Figure 7a). In contrast, SF
mDCs produced considerably higher levels of IL-10 following
PGN stimulation than did the PB comparators. IL-12 p70, IL-2
and IL-4 levels were below the limit of sensitivity of the assay
in all cultures. Furthermore, coincident addition of PGN with
GM-CSF induced higher levels of maturation marker
expression (compared with GM-CSF alone), particularly
CCR7, CD40, CD80 and CD83 (Figure 7b).
We next examined the cytokine release by pDCs. CpG ODN
2216 stimulated the release of large amounts of both IFN-α
and TNF-α, from both PB-derived and SF-derived DCs. How-
ever, only SF pDCs produced IL-10 following CpG ODN
2216 stimulation (Figure 8a). Neither IL-2 nor IL-4 release was
detected under these conditions. Upon phenotypic analysis,
the upregulation of CCR7, CD80 and CD83 (Figure 8b) after
CpG ODN 2216 stimulation was observed. Finally, we noted
that growth factor alone, namely GM-CSF or IL-3, was suffi-
cient to promote maturation marker expression but did not
induce cytokine production.
Together these data indicate that SF DC subsets retain the
capacity to upregulate maturation markers and respond to TLR
agonists, and that the latter are necessary to promote optimal
maturation and cytokine production.
Discussion
The relative role of innate and adaptive components of the host
immune response to inflammatory synovitis is of considerable
current interest. DCs comprise a heterogeneous network of
professional antigen-presenting cells, capable not only of pre-
senting antigen and inducing subsequent adaptive immune
responses, but also of sensing the inflammatory environment
and contributing to the cytokine milieu therein. While
implicated in the pathogenesis of RA and PsA [19,33-37],
prior analysis of DC subsets has been hampered by a lack of
specific DC markers and reliable quantitation methodologies.
The present study has utilised the pDC-specific marker
CD303 (BDCA-2) and the mDC marker CD1c within a sensi-
tive assay system to provide enumeration and phenotypic anal-
ysis of the DC subsets in PB and SF from PsA patients and
RA patients. Thereafter we have utilised novel markers to
purify DC subpopulations and perform a functional evaluation
of their activation potential ex vivo. Finally we have for the first
time attempted a phenotypic description of DC subsets in PsA
and compared them with those in RA.
We observed a reduction in circulating PB pDC and PB mDC
populations in RA patients, and in pDC populations in PsA
Table 2
Absolute number of cells (×104/ml) in rheumatoid arthritis and psoriatic arthritis peripheral blood and matched synovial fluid
White blood cells Myeloid dendritic cells Plasmacytoid dendritic cells
Rheumatoid arthritis (n = 6)
Peripheral blood 652 ± 93.7 1.36 ± 0.641 0.582 ± 0.211
Synovial fluid 1020 ± 235 11.6 ± 3.12 3.24 ± 1.71
Psoriatic arthritis (n = 6)
Peripheral blood 969 ± 240 1.39 ± 0.420 0.761 ± 0.220
Synovial fluid 2860 ± 351 37.5 ± 8.72 7.20 ± 2.23
Data presented as the mean ± standard error of the mean.
Figure 6
Detecting interferon alpha in synovial fluid Detecting interferon alpha in synovial fluid. Rheumatoid arthritis (RA) 
synovial fluid (SF), psoriatic arthritis (PsA) SF and osteoarthritis (OA) 
SF contain interferon alpha (IFN-α). The level of IFN-α in SF from RA 
patients (n = 18), PsA patients (n = 15) and OA patients (n = 8) was 
measured by ELISA. Squares indicate individual samples expressed on 
a log scale. -, median.Available online http://arthritis-research.com/content/8/1/R15
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patients. That this was not observed in prior investigation
probably reflects less sensitive methodologies [52,53] and the
identification of subsets based upon CD123 expression,
which is also expressed by basophils [54], haematopoietic
progenitor cells [55], endothelial cells [56], monocytes, eosi-
nophils and small subsets of lymphocytes [57]. The observed
decrease in DC numbers is not due to steroid therapy, which
has been reported to reduce DC numbers [58] and function
[59], as patients on corticosteroids were excluded from the
study.
Decreased PB DC numbers most probably reflect DC migra-
tion from the circulation and accumulation to the inflamed syn-
ovial compartment. This is consistent with previous studies
[52,53,60] and with our own data, indicating comparatively
high numbers of mDCs and pDCs in SF effusions from both
PsA patients and RA patients. In addition, the SF DC subset
expression of CD62L (normally cleaved from the cell surface
after leukocyte tethering and rolling across high endothelial
venules [61]) was lower in both PsA SF and RA SF compared
with the peripheral blood compartment, further indicative of
migration.
In preliminary studies, we have utilised these novel markers to
identify pDCs in RA, PsA and in OA synovial membrane (SM)
itself (see Additional file 1). Future detailed phenotypic analy-
sis of such membrane DC subsets is now necessary, and will
offer insight into the migratory pathway and functional activi-
ties of distinct DC subsets in chronic synovitis. Finally, the
trend towards decreased PB pDC numbers in the OA
patients, although not significant, may be indicative of altered
DC migration toward the synovial compartment. OA is associ-
ated with synovial hypertrophy, hyperplasia, local inflammation
and recurrent effusions [62].
Figure 7
Cytokine release and phenotypic changes following mDC exposure to TLR agonist Cytokine release and phenotypic changes following mDC exposure to TLR agonist. Synovial fluid (SF) myeloid dendritic cells (mDCs) mature and 
release tumour necrosis factor alpha (TNF-α) at comparable levels with healthy peripheral blood (PB) mDCs, but only SF mDCs release IL-10. 
Cytokine release and the maturation status of mDCs purified from healthy control PB (n = 3) or inflammatory arthritis SF (rheumatoid arthritis, n = 2; 
psoriatic arthritis, n = 1) were assessed after 24-hour incubation with granulocyte–macrophage colony-stimulating factor (GM-CSF)-supplemented 
media alone or containing Staphylococcus aureus peptidoglycan (PGN) (10 µg/ml). (a) The concentrations of TNF-α and IL-10 in supernatant from 
the cultures were determined by multiplex analysis and were expressed as release per 5 × 104 cells. Squares indicate individual donors. (b) Matura-
tion and co-stimulation marker expression was determined by flow cytometry, and one representative example from each of the healthy control PB 
and inflammatory arthritis SF groups are shown.Arthritis Research & Therapy    Vol 8 No 1    Jongbloed et al.
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Other factors may operate in regulating detectable blood DC
numbers, however, particularly within the bone marrow – in
which it is increasingly recognised that functional maturation
defects may exist for leukocyte lineages [63]. For example,
reduced pDC numbers in circulating PB could reflect elevated
TNF-α expression [64,65]: TNF-α is known to inhibit fms-like
tyrosine kinase 3-ligand-driven differentiation of pDC from
bone marrow progenitors [51,66]. Future studies will be
required to establish the circulating half-life and tissue destina-
tion of DC subsets in the context of inflammatory arthropa-
thies, and indeed of the effect of cytokine blockade on such
parameters. It should also be noted that reduced circulating
DC subsets have been demonstrated in several other inflam-
matory disorders, including systemic lupus erythematosus
[48] and chronic active hepatitis [67], and that regulatory
pathways in such diseases may also be informative in elucidat-
ing DC function in synovitis.
A further novel observation was the reduced CD62L expres-
sion on both DC subsets in PsA PB and RA PB. Reduced
CD62L expression on RA PB CD3+ and CD19+ lymphocytes,
monocytes and granulocytes [68] has been linked to immuno-
suppressive therapies including methotrexate [69], and a sim-
ilar mechanism could explain our observations. However,
downregulation of adhesion molecules such as CD62L is
necessary for the release of CD34+ progenitors to the PB
[70], and it is possible that a CD62Llo PB DC population may
indicate altered recirculation or modified release of bone mar-
row DC precursors.
Purified SF pDCs were recently reported to exhibit a relatively
immature phenotype given their inflammatory environment
[52,53]. Similar observations have been made for mDCs
[26,60]. We now confirm these observations in RA and extend
the data to include PsA-derived cells, indicating that the
inflamed synovial compartment per se can sustain immature
Figure 8
Cytokine release and phenotypic changes following pDC exposure to TLR agonst Cytokine release and phenotypic changes following pDC exposure to TLR agonst. Synovial fluid (SF) plasmacytoid dendritic cells (pDCs) mature 
and release interferon alpha (IFN-α) and tumour necrosis factor alpha (TNF-α) at comparable levels with healthy control peripheral blood (PB) pDCs, 
but only SF pDCs release IL-10. Cytokine release and the maturation status of pDCs purified from healthy control PB (n = 3) and inflammatory arthri-
tis SF (rheumatoid arthritis, n = 2; psoriatic arthritis, n = 1) were assessed after 24-hour incubation with IL-3-supplemented media alone or contain-
ing the TLR9 agonist CpG ODN 2216 (3.2 µg/ml). (a) The concentrations of IFN-α, TNF-α and IL-10 in supernatant from cultures was determined 
by multiplex and ELISA analysis, and was expressed as release per 5 × 104 cells. Squares indicate individual donors. (b) Maturation and co-stimula-
tion marker expression was determined by flow cytometry, and one representative example from each of the healthy control PB and inflammatory 
arthritis SF groups are shown.Available online http://arthritis-research.com/content/8/1/R15
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DCs capable by inference of antigen sensing, capture and,
ultimately, presentation. Upon removal from the SF, both
mDCs and pDCs were capable of increased maturation
marker expression and, provided with TLR agonist activation,
were capable of cytokine release. There does not therefore
appear to be an intrinsic functional defect of DCs. Whereas
TLR2 or TLR9 stimulation was not sufficient to induce
substantial IL-10 release from healthy PB mDCs and pDCs, it
was sufficient for IL-10 release from PsA SF and RA SF puri-
fied cells.
The functional implications of this observation are unclear and
require further examination to include other TLR agonists and
DC activation conditions. In particular we now wish to examine
the cross-regulation of mDC and pDC subsets in the context
of inflammatory synovitis. That said, the technical demands of
isolating primary DCs from an inflamed compartment
(particularly pDCs) are not insignificant and place limitations
on feasible functional analyses. Very few groups have thus far
attempted formal functional evaluation of purified DC subsets
from any inflamed tissue. Our approach combines a broad but
pragmatic approach to start to examine DC function ex vivo.
Future technical refinements will be required to perform the
desired extensive in vitro analyses of DC function that will
more comprehensively address their functional role.
These are the first data to investigate purified DC subsets in
PsA patients. Prior studies have identified pDC in cutaneous
psoriasis and increased type I IFN expression in psoriatic
plaques after application of a TLR agonist [71]. Numerous
data indicate a role of T cells in PsA pathogenesis [72]; deter-
mining the functional role of both pDCs and mDCs in PsA
synovium should therefore be informative. The present study
provides the essential pre-requisite for such studies in deter-
mining the presence, enumeration and function of each subset
in PB and SF.
IFN-α was detected in SF in both RA patients and PsA
patients. The role for this cytokine in synovial pathogenesis is
indicated by numerous reports linking IFN-α therapy to induc-
tion of RA and PsA in patients with no pre-existing clinical
arthritis [73-75]. Moreover, IFN-α is sufficient to drive mono-
cyte differentiation to mDCs in systemic lupus erythematosus
patients [76]. The significantly increased mDC:pDC ratio iden-
tified in SF may indicate in situ differentiation of monocytes
shed from the synovial lining layer to mDCs, driven in part by
IFN-α in the fluid. It is therefore intriguing to consider a local
cytokine-mediated feedback loop whereby pDC IFN-α release
promotes local mDC maturation. Consistent with this, we have
recently observed that PsA SF is capable of inducing differen-
tiation of mDCs from PB-derived monocytes (unpublished
observations).
While only mature DCs are able to induce the activation of T
cells and the differentiation of B cells into antibody-producing
plasma cells, immature DCs are able to capture antigen at
picomolar and nanomolar concentrations [77]. In the steady
state, presentation of these self-antigens should sustain toler-
ance. However, the presentation of these antigens within an
inflammatory context, such as the inflamed synovial
compartment in susceptible individuals, may lead to chronic
inflammation and autoimmune disease. SF apparently contains
a pool of immature DC subsets of both mDC and pDC lineage
that could facilitate (auto)antigen capture, and thereby the ini-
tiation or perpetuation (neoepitopes) of autoimmunity.
Conclusion
In summary, we have performed a comparative evaluation of
RA and PsA circulating and SF DC subsets. Our data show
that mDC and pDC numbers are significantly decreased in RA
PB and that pDCs are significantly decreased in PsA PB, and
that both subsets exhibit reduced CD62L expression. These
data indicate an altered recirculation or circulating half-life for
DC subsets in inflammatory arthritis. Both mDCs and pDCs
are present in SF from RA and PsA, with pDCs expressing an
immature phenotype whereas mDCs express a semi-mature
phenotype. Synovial fluid DCs remain responsive to TLR ago-
nism, exhibiting maturation ex vivo and cytokine release.
Future studies are now required to evaluate those factors that
prevent local maturation of DCs in synovial fluid and to deter-
mine the functional significance of immature DCs maintained
in the fluid compartment of the inflamed joint.
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